Novacyt S.A. Notice of Results

RNS Number : 8234D

Novacyt S.A.

12 September 2024

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Notice of Half Year 2024 Results and Investor Presentation

 

Paris, France, and Eastleigh and Manchester, UK - 12 September 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its unaudited financial results for the six months ended 30 June 2024 on Thursday, 26 September 2024.

 

Investor webinar

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the HY 2024 results will take place at 11.00am BST on Thursday, 26 September 2024.

 

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation.

 

Investors can sign up for the webinar via:

 

https://www.investormeetcompany.com/novacyt-sa/register-investor

 

Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

 

Contacts

 

Novacyt SA			https://novacyt.com/investors
Lyn Rees, Chief Executive Officer			Via Walbrook PR
Steve Gibson, Chief Financial Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)				[phone]
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Deutsche Numis (Joint Broker)				[phone]
Freddie Barnfield / Duncan Monteith / Michael Palser
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit		[phone] [e-mail] / [e-mail]
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings			[phone] or [e-mail] [phone] / [phone]  [phone] / [phone]

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical	Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests ·    Precision Medicine: DPYD genotyping assay ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: ·    Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the research industry: ·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry ·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NOREADNFFSDLEFA